Table 7. . Non-temporal scenario analysis.
| Treatment comparisons | Utilization mix/cost savings | 1st year | 2nd year | 3rd year | 4th year | 5th year |
|---|---|---|---|---|---|---|
| Dronedarone vs other AADs | Projected utilization | 10% | 12% | 15% | 18% | 20% |
| Savings (in PPPM) | -$5.09 | -$11.61 | -$21.39 | -$31.17 | -$37.69 | |
| Dronedarone vs RC + Ablation | Projected utilization | 30% | 35% | 40% | 45% | 50% |
| Savings (in PPPM) | -$28.07 | -$113.69 | -$199.31 | -$284.93 | -$370.54 | |
| Dronedarone vs Ablation | Projected utilization | 25% | 30% | 35% | 40% | 45% |
| Savings (in PPPM) | -$31.57 | -$113.67 | -$195.76 | -$277.85 | -$359.94 | |
| Dronedarone + RC vs AADs + Rate Control | Projected utilization | 10% | 13% | 17% | 22% | 28% |
| Savings (in PPPM) | $3.95 | $8.82 | $15.30 | $23.41 | $33.14 | |
| Dronedarone vs RC | Projected utilization | 3% | 4% | 5% | 6% | 8% |
| Savings (in PPPM) | $1.33 | $3.01 | $4.69 | $6.37 | $9.74 | |
| Dronedarone + Ablation vs other AADs + Ablation | Projected utilization | 15% | 20% | 25% | 30% | 35% |
| Savings (in PPPM) | $4.65 | $14.96 | $25.26 | $35.57 | $45.88 | |
| Dronedarone + RC + Ablation vs AADs + Rate Control + Ablation | Projected utilization | 15% | 20% | 25% | 30% | 35% |
| Savings (in PPPM) | $6.41 | $16.11 | $25.81 | $35.51 | $45.21 | |
| Dronedarone vs RC vs Ablation | Projected utilization | 3% | 4% | 5% | 6% | 8% |
| Savings (in PPPM) | $0.39 | $0.80 | $1.21 | $1.63 | $2.45 |
PPPM positive cost results favor the reference scenario, while negative PPPM cost results favor the projected scenario.
AADs: Antiarrhythmic drug; PPPM: Per patient in the target population per month; RC: Rate control medication.